LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models

LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models

Abstract Background Castrate resistant prostate cancer (CRPC) is often driven by constitutively active forms of the androgen receptor such as the V7 splice variant (AR-V7) and commonly becomes resistant to established hormonal therapy strategies such as enzalutamide as a result. The lysine demethyla...

Full description

Bibliographic Details
Main Authors: Sergio Regufe da Mota, Sarah Bailey, Rosemary A. Strivens, Annette L. Hayden, Leon R. Douglas, Patrick J. Duriez, M. Teresa Borrello, Hanae Benelkebir, A. Ganesan, Graham Packham, Simon J. Crabb
Format: Article
Language:English
Published: BMC 2018-05-01
Series:Cancer Cell International
Subjects:
Androgen receptor
LSD1
Prostate cancer
Castration resistance
Enzalutamide
AR-V7 splice variant
Online Access:http://link.springer.com/article/10.1186/s12935-018-0568-1

Internet

http://link.springer.com/article/10.1186/s12935-018-0568-1

Similar Items